In contrast, less prevalent actionable fusions exhibited tumour type specificity including CCDC6-RET fusions in thyroid and lung cancer, FGFR2-BICC1 in cholangiocarcinoma, PTPRZ1-MET in glioblastoma, EIF3E-RSPO2 and PTPRK-RSPO3 in colorectal cancer and KIF5B-RET in NSCLC as previously reported [3, 25–28]. This evidence concerns the gene CCDC6 and non-small cell lung carcinoma.